[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100399194":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":10,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":70,"sex":71,"minAge":10,"maxAge":72,"enrollmentInfo":73,"targetDuration":10,"studyType":76,"phases":10,"briefSummary":77,"conditions":78,"keywords":10,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Chinese University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Childhood Leukemia",null,"Peripheral blood and bone marrow samples are collected for genetic analysis, invitro drug sensitivity test and animal experiment.",[13,14,15],"Genetic: RNA-seq","Genetic: whole exon sequencing","Other: Cytogenetics test",[17,22,26],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"GENETIC","RNA-seq","Gene expression and fusion transcripts analysis",[9],{"type":18,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"whole exon sequencing","Genetic alternation analysis",[9],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"Cytogenetics test","Remission and relapse are monitored by cytogenetic analyses.",[9],[31],{"name":32,"affiliation":5,"role":33},"Kam Tong Leung, Ph. D.","PRINCIPAL_INVESTIGATOR",[35,40],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Kathy Chan, Ph. D.","CONTACT","852-35052858","kathyyychan@cuhk.edu.hk",{"name":32,"role":37,"phone":41,"phoneExt":10,"email":42},"852-35133176","ktleung@cuhk.edu.hk",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":10,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Hong Kong Children Hospital","RECRUITING","Hong Kong","Hksar","China","CN",{"type":52,"coordinates":53},"Point",[54,55],114.17469,22.27832,{"lat":55,"lon":54},[58],{"name":59,"role":37,"phone":41,"phoneExt":10,"email":42},"Kam Tong LEUNG, Ph. D.",{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Kathy Chan","Scientific Officer","100399194","advanced-translational-research-on-childhood-leukemia-100399194",false,"NCT04478006","Advanced Translational Research on Childhood Leukemia","Driving Therapeutic Progress of Childhood Leukemia Through Advanced Translational Research With Immediate and Long-term Impact. Precision Medicine for Childhood Leukemia.","List of inclusion criteria:\n\n1. acute lymphoblastic leukemia (ALL) or\n2. acute myeloid leukemia (AML) or\n\n3 .mixed phenotype acute leukemia (MPAL) or\n\n4\\. juvenile myelomonocytic leukemia (JMML) or\n\n5\\. myelodysplastic syndromes (MDS) or\n\n6\\. normal bone marrow donor\n\nList of exclusion criteria:\n\n1. This study will not recruit subjects who are unable to understand English or Chinese.\n2. Patient or parent refusal",true,"ALL","18 Years",{"count":74,"type":75},300,"ESTIMATED","OBSERVATIONAL","Prognosis of children with leukemia, the most common pediatric cancer, has improved markedly. Yet, relapse still occurs in 15-40% of patients with a probability of survival of \\\u003C50%, which is unlikely to be boosted by intensification of standard chemotherapy due to overwhelming toxicity. The advent of effective and safe targeted therapies for high-risk cases is therefore imperative. This study constitutes two research projects aiming at driving therapeutic advances.",[9],"2026-02-01",{"date":81,"type":82},"2026-02-03","ACTUAL",{"date":84,"type":82},"2020-07-01",{"date":86,"type":75},"2028-06-01",{"name":5,"class":6},1]